Department of Health written question – answered at on 13 June 2016.
Lord Hunt of Kings Heath
Shadow Spokesperson (Health), Shadow Deputy Leader of the House of Lords
To ask Her Majesty’s Government, in the light of the draft recommendation from NICE not to recommend the drug Strensiq for the treatment of hypophosphatasia for critically ill infants who are otherwise likely to die, what other treatment options are available.
Lord Prior of Brampton
The Parliamentary Under-Secretary of State, Department of Health
The National Institute for Health and Care Excellence (NICE) is currently evaluating Strensiq (asfotase alfa) for the treatment of paediatric-onset hypophosphatasia under its highly specialised technologies programme.
NICE’s draft guidance, published in December 2015 for consultation, did not recommended asfotase alfa. However this is not NICE’s final guidance to the National Health Service.
NICE’s draft guidance states that there are currently no other treatments available that specifically prevent or delay the progression of hypophosphatasia.
Yes2 people think so
No1 person thinks not
Would you like to ask a question like this yourself? Use our Freedom of Information site.
